Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
94,568,251
-
Shares change
-
-224,925
-
Total reported value, excl. options
-
$85,611,694
-
Value change
-
-$260,136
-
Put/Call ratio
-
1.6%
-
Number of buys
-
36
-
Number of sells
-
29
-
Price
-
$0.9053
Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q3 2024
As of 30 Sep 2024 Lineage Cell Therapeutics, Inc. - Common shares (LCTX) had 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 94,568,251 shares of stock of the company.
Largest 10 holders included BROADWOOD CAPITAL INC, BlackRock, Inc., VANGUARD GROUP INC, Defender Capital, LLC., Logos Global Management LP, RAFFLES ASSOCIATES LP, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, MAI Capital Management, and BANK OF AMERICA CORP /DE/.
This table shows 112 institutional shareholders of the security as of 30 Sep 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.